Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
44.82
+0.70 (+1.59%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
November 29, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Proposed Public Offering
November 29, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
November 28, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Xenon Pharmaceuticals: Q3 Earnings Insights
↗
November 08, 2023
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
↗
November 07, 2023
Via
Benzinga
Expert Ratings for Xenon Pharmaceuticals
↗
July 17, 2023
Via
Benzinga
Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst
↗
November 27, 2023
Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20...
Via
Benzinga
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 27, 2023
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
↗
November 27, 2023
The company's epilepsy drug also showed promise as a depression treatment.
Via
Investor's Business Daily
What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today?
↗
November 27, 2023
Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of...
Via
Benzinga
Analyst Ratings for Xenon Pharmaceuticals
↗
June 15, 2023
Via
Benzinga
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Near the Top of Equities by Percentage Gain on 11/27
November 27, 2023
Via
Investor Brand Network
Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday
↗
November 27, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) gained during Monday’s session after the company...
Via
Benzinga
Topics
Stocks
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
November 27, 2023
Conference call today at 8:30 am ET
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Why Is Neurocrine Biosciences Stock Trading Lower Today?
↗
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
November 09, 2023
Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
November 01, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For November 8, 2023
↗
November 08, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
Via
Benzinga
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
October 09, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 06, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Making Surprising Moves in Tuesday Session
September 26, 2023
Via
Investor Brand Network
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
September 14, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
September 12, 2023
Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
September 04, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
August 31, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
August 08, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
August 02, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.